Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666055 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL664990 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL28946753 | 0.82 | CYP2C9 (0.40) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL66681 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL2998678 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL5204752 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL29114645 | 0.81 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL1199043 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL9614515 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL1199042 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-02-23 | — | — | US | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| US-11192861-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-02-18 | — | — | US | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| US-10633345-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20160164075-A1 | PROCESS FOR PRODUCING AN ACTIVE CATHODE MATERIAL COMPRISING A MIXTURE OF A METAL OXIDE AND A METAL SULFIDE AND USE OF THE ACTIVE CATHODE MATERIAL IN RECHARGEABLE ELECTROCHEMICAL CELLS | BASF SE (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3022786-A1 | PROCESS FOR PRODUCING ACTIVE CATHODE MATERIAL COMPRISING MIXTURE OF METAL OXIDE AND METAL SULFIDE AND USE OF ACTIVE CATHODE MATERIAL IN RECHARGEABLE ELECTROCHEMICAL CELLS | BASF SE (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-4320070-A | ION EXCHANGE RESIN CATALYST | PPG INDUSTRIES, INC. (US) | 1982-03-16 | — | — | US | disclosed |
| US-4273725-A | Process for preparing chlorothiolformates | PPG INDUSTRIES, INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4268456-A | FROM A MERCAPTAN AND PHOSGENE, QUATERNARY AMMONIUM SALT CATALYST | PPG INDUSTRIES, INC. (US) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | ALDH1A1 838/4885CYP1A2 308/4885CYP2C9 167/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885CYP1A2 297/4885CYP2C9 690/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1220/4885CYP1A2 1437/4885CYP2C9 1062/4885 |
| US-11192861-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1220/4885CYP1A2 1437/4885CYP2C9 1062/4885 |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1220/4885CYP1A2 1437/4885CYP2C9 1062/4885 |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885CYP1A2 1409/4885CYP2C9 1033/4885 |
| US-10633345-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ALDH1A1 1065/4885CYP1A2 1525/4885CYP2C9 1018/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885CYP1A2 1409/4885CYP2C9 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.